Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 4/2010

01-08-2010 | Viewpoint

BRCA1: linking HOX to breast cancer suppression

Authors: Kideok Jin, Saraswati Sukumar

Published in: Breast Cancer Research | Issue 4/2010

Login to get access

Abstract

Homeobox (HOX) genes play key roles in embryogenesis and tissue differentiation. Recently, a number of groups have reported altered HOX gene expression in breast cancer. However, the mechanism of HOX gene regulation and the search for direct targets of its transcriptional regulatory function have been minimally fruitful. Recently, Gilbert and colleagues reported that HOXA9 restrains breast cancer progression by upregulation of BRCA1, a tumor suppressor. This finding raises our hope that more, rather elusive targets of HOX genes important in tumor progression or suppression will be found in the future.
Literature
1.
Krumlauf R: Hox genes in vertebrate development. Cell. 1994, 78: 191-201. 10.1016/0092-8674(94)90290-9.CrossRefPubMed
2.
Cillo C, Cantile M, Faiella A, Boncinelli E: Homeobox genes in normal and malignant cells. J Cell Physiol. 2001, 188: 161-169. 10.1002/jcp.1115.CrossRefPubMed
3.
Abate-Shen C: Deregulated homeobox gene expression in cancer: cause or consequence?. Nat Rev Cancer. 2002, 2: 777-785. 10.1038/nrc907.CrossRefPubMed
4.
Raman V, Martensen SA, Reisman D, Evron E, Odenwald WF, Jaffee E, Marks J, Sukumar S: Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature. 2000, 405: 974-978. 10.1038/35016125.CrossRefPubMed
5.
Trivedi CM, Patel RC, Patel CV: Homeobox gene HOXA9 inhibits nuclear factor-kappa B dependent activation of endothelium. Atherosclerosis. 2007, 195: e50-60. 10.1016/j.atherosclerosis.2007.04.055.CrossRefPubMed
6.
Trivedi CM, Patel RC, Patel CV: Differential regulation of HOXA9 expression by nuclear factor kappa B (NF-kappaB) and HOXA9. Gene. 2008, 408: 187-195. 10.1016/j.gene.2007.11.001.CrossRefPubMed
7.
Wu X, Chen H, Parker B, Rubin E, Zhu T, Lee JS, Argani P, Sukumar S: HOXB7, a homeodomain protein, is overexpressed in breast cancer and confers epithelial-mesenchymal transition. Cancer Res. 2006, 66: 9527-9534. 10.1158/0008-5472.CAN-05-4470.CrossRefPubMed
8.
Daftary GS, Taylor HS: Endocrine regulation of HOX genes. Endocr Rev. 2006, 27: 331-355. 10.1210/er.2005-0018.CrossRefPubMed
9.
Shah N, Sukumar S: The Hox genes and their roles in oncogenesis. Nat Rev Cancer. 2010, 10: 361-371. 10.1038/nrc2826.CrossRefPubMed
10.
Gilbert PM, Mouw JK, Unger MA, Lakins JN, Gbegnon MK, Clemmer VB, Benezra M, Licht JD, Boudreau NJ, Tsai KK, Welm AL, Feldman MD, Weber BL, Weaver VM: HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype. J Clin Invest. 2010, 120: 1535-1550.CrossRefPubMedPubMedCentral
11.
Reynolds PA, Sigaroudinia M, Zardo G, Wilson MB, Benton GM, Miller CJ, Hong C, Fridlyand J, Costello JF, Tlsty TD: Tumor suppressor p16INK4A regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells. J Biol Chem. 2006, 281: 24790-24802. 10.1074/jbc.M604175200.CrossRefPubMed
12.
Chen F, Capecchi MR: Paralogous mouse Hox genes, Hoxa9, Hoxb9, and Hoxd9, function together to control development of the mammary gland in response to pregnancy. Proc Natl Acad Sci USA. 1999, 96: 541-546. 10.1073/pnas.96.2.541.CrossRefPubMedPubMedCentral
13.
Look AT: Oncogenic transcription factors in the human acute leukemias. Science. 1997, 278: 1059-1064. 10.1126/science.278.5340.1059.CrossRefPubMed
14.
Bruhl T, Urbich C, Aicher D, Acker-Palmer A, Zeiher AM, Dimmeler S: Homeobox A9 transcriptionally regulates the EphB4 receptor to modulate endothelial cell migration and tube formation. Circ Res. 2004, 94: 743-751. 10.1161/01.RES.0000120861.27064.09.CrossRefPubMed
Metadata
Title
BRCA1: linking HOX to breast cancer suppression
Authors
Kideok Jin
Saraswati Sukumar
Publication date
01-08-2010
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 4/2010
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2600

Other articles of this Issue 4/2010

Breast Cancer Research 4/2010 Go to the issue

Letter

RAD51C germline mutations in breast and ovarian cancer patients

Viewpoint

Ovarian steroid hormones: what's hot in the stem cell pool?

Research article

Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells

Research article

Breast cancer incidence and overdiagnosis in Catalonia (Spain)

Research article

Mammostrat®as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy

Research article

Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits